Azoxin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azoxin

Property Description
Active Ingredient Azithromycin
Pharmacological Class Macrolide antibiotic (specifically, an azalide)
Form Tablets, oral suspension, intravenous (IV) solution
Common Use Combats various bacterial infections
Origin Semisynthetic (derived from Erythromycin)

Azoxin: Defining the Antimicrobial Agent

Azoxin is a semisynthetic medicine whose active component is the substance Azithromycin. It is formally classified as a macrolide antibiotic, which places it among specialized antimicrobial agents used to target illnesses caused by susceptible bacteria. This classification confirms its primary role is to fight bacterial illness, and it is clinically recognized for its broad-spectrum application against different bacterial strains. This medicine works by stopping the growth of bacteria.

Azithromycin belongs to the azalide subclass, a key differentiating feature from older macrolide drugs. This modified molecular structure demonstrates superior distribution into tissue compartments. The unique tissue distribution of Azithromycin defines it as an agent demonstrating utility in infections where high tissue concentration is beneficial.

Composition, Origin, and Preparation

The medicine is supplied as a single-ingredient product, containing only Azithromycin as the active therapeutic substance, alongside necessary inactive ingredients. Azithromycin itself is classified as a semisynthetic compound, meaning its structure is derived through chemical manufacturing by modification of the naturally produced antibiotic erythromycin. Azoxin is available in several high-level dosage forms, including conventional tablets, a liquid oral suspension (often preferred for pediatric patients), and an injectable solution for intravenous administration, allowing medical professionals flexibility in delivery based on the patient group and context.

The General Principle of its Action

The core purpose of Azoxin is to act as an effective countermeasure against certain bacterial infections. The medicine achieves this general benefit by directly interfering with the bacteria’s vital processes. Its mechanism fundamentally involves inhibiting bacterial growth and multiplication; it stops the synthesis of essential proteins within the bacterial cell, thereby reducing the bacterial load and assisting the body's natural defenses in resolving the infection.

What side effects are possible with Azoxin?

Possible Side Effects and Safety Information

The safety profile of Azoxin (azithromycin) is characterized by common gastrointestinal effects and warnings regarding rare but serious systemic risks, all strictly based on governmental regulatory documents.

Adverse Reactions

The most common adverse reactions observed in clinical trials, particularly within the Gastrointestinal System Organ Class, include diarrhea (5–14%), nausea (3–18%), abdominal pain, and vomiting.

Serious and Clinically Significant Adverse Reactions

Official regulatory labeling includes mandatory warnings for several serious or fatal adverse reactions:

  • Cardiotoxicity: The potential for QT interval prolongation and torsades de pointes (a potentially fatal irregular heart rhythm) has been reported. Observational studies suggest an increased short-term risk of acute cardiovascular death compared to other antibiotics in certain adult patient populations.
  • Hepatotoxicity: Severe and sometimes fatal hepatotoxicity has been reported. Discontinuation is required immediately if signs of hepatitis occur.
  • Hypersensitivity: Fatal allergic reactions and severe skin reactions (such as Stevens-Johnson syndrome) have occurred.
  • Infections: Risk of Clostridioides difficile-Associated Diarrhea (CDAD).
  • Neuromuscular: Exacerbation of muscle weakness in persons with myasthenia gravis.

Safety Considerations

  • Population Specific: Geriatric patients may be more susceptible to torsades de pointes arrhythmias. Use in neonates (treatment up to 42 days of life) has been associated with Infantile Hypertrophic Pyloric Stenosis (IHPS).
  • Restrictions: Azoxin is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior Azoxin use. Caution is required in patients with pre-existing QT prolongation or other proarrhythmic conditions.

Overdose and Emergency Response

Overdose Manifestations and Critical Risk

Official regulatory information states that Azoxin overdosage may present as an exaggeration of known adverse effects, primarily involving the gastrointestinal system. Documented manifestations include severe nausea, vomiting, and diarrhea. The most significant risk associated with overdosage is the potential for cardiac system involvement.

High exposure is associated with prolongation of the cardiac repolarization phase, which may result in a prolonged QT interval on an ECG. This condition carries a serious risk for developing Torsades de pointes, a potentially life-threatening ventricular arrhythmia. Elderly and female patients are noted in warnings as having an increased baseline risk for prolonged repolarization.

Required Emergency Actions

Any suspected overdosage requires the individual to seek immediate medical attention. Regulatory guidelines mandate that emergency services be contacted without delay if severe signs are present, such as collapse, seizure, trouble breathing, or loss of consciousness.

Treatment focuses on general symptomatic and supportive measures. Due to the critical nature of the cardiac risk, continuous monitoring of the cardiac rhythm is a necessary component of care. The labeling explicitly states that no specific antidote is known for Azithromycin overdosage, though the administration of medicinal charcoal may be considered as a supportive measure.

Therapeutic Uses of Azoxin

What Azoxin Treats: Main Uses and Benefits

Azoxin (Azithromycin) is commonly used in situations involving certain distressing symptoms linked to bacterial causes. This medication is indicated for infections across several body systems, confirming its role in supportive symptom management.


Managing Acute and Targeted Infections

This includes conditions presenting with systemic or localized discomfort in areas like the sinuses, throat, middle ear, and lower airways (like community-acquired pneumonia and bronchitis); specific bacterial illnesses, such as certain sexually transmitted infections (STIs); and uncomplicated skin infections. Azoxin is applied in addressing conditions where symptoms become more disruptive during flare-ups.

Azoxin helps address symptoms related to physical discomfort such as persistent coughing, chest discomfort, acute ear pain, and systemic fever. This provides supportive relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability during symptomatic phases. Furthermore, it is used for managing symptoms that become more disruptive during flare-ups in patients with long-term respiratory issues (e.g., Asthma, Cystic Fibrosis), supporting general well-being during symptomatic phases.


Quick Fact: Symptomatic Support

Azoxin is commonly used when groups of symptoms, like fever and acute localized pain, appear suddenly or fluctuate, providing symptomatic assistance and easing the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Azoxin?

Eligibility for Azoxin (Azithromycin) is determined by a patient's medical history and specific health status, as defined in official regulatory prescribing information.


Absolute Contraindications (Cannot Use)

Azoxin is contraindicated (absolutely prohibited) for use in patients with:

  • A known history of a severe allergic reaction (hypersensitivity) to Azithromycin, Erythromycin, or any other macrolide or ketolide antibiotic.
  • A history of cholestatic jaundice or hepatic dysfunction specifically linked to previous use of Azithromycin.

Condition-Based Restrictions and Special Use Populations

Certain groups require caution or have specific limitations on eligibility:

Population/Condition Eligibility Status or Restriction
Pediatric Patients Safety and effectiveness are not established for most uses in infants under 6 months of age.
Severe Renal Impairment Caution is required in patients with severe renal impairment (GFR < 10 mL/min).
Severe Hepatic Disease Use is not recommended in patients with severe liver disease.
Cardiac Conditions Caution is mandatory in patients with known QT prolongation or other proarrhythmic conditions, including the elderly who may be more susceptible.
Pregnancy/Lactation Use during pregnancy is advised only if clearly needed. Azithromycin is secreted into human milk.

Eligibility is defined by regulatory bodies to ensure that the medicine is used safely and appropriately.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Azoxin (Azithromycin) is based on formal regulatory documentation detailing specific pharmacokinetic and pharmacodynamic effects with co-administered substances. All interaction data presented is derived exclusively from official government health authority sources, ensuring a neutral and label-aligned description.

Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type Interacting Substance/Class Official Documented Outcome
Pharmacodynamic QT-prolonging drugs (e.g., Class IA/III Antiarrhythmics) Co-administration increases the risk of QT interval prolongation and Torsades de Pointes [FDA].
Pharmacodynamic Warfarin (Oral Anticoagulant) May increase coagulation times, necessitating careful monitoring of prothrombin time [FDA].
Pharmacokinetic Nelfinavir (HIV Protease Inhibitor) Increases Azoxin plasma exposure (AUC and Cmax), requiring monitoring for known Azoxin side effects [FDA].
Pharmacokinetic Antacids (Aluminum/Magnesium Hydroxide) Reduces Azoxin capsule's maximum plasma concentration ( C max) by 24%; AUC is unchanged [FDA].

Formulations and Specific Conditions

Administration of the Azoxin oral suspension formulation with food increases its C max by 56%, a pharmacokinetic effect that varies by formulation. Furthermore, patients with uncorrected hypokalemia or hypomagnesemia are identified as having a heightened risk for the QT prolongation pharmacodynamic interaction [FDA]. Some regulatory bodies formally state that Ergot Derivatives (e.g., Ergotamine) are contraindicated with Azoxin due to the theoretical risk of ergotism.

Mechanism of Action

Targeted Blockade of Bacterial Protein Assembly

Azoxin acts directly as an inhibitor on the bacterial 50S ribosomal subunit, binding specifically to the 23S ribosomal RNA component. This molecular interaction physically blocks the translocation step of peptide chain elongation, functionally halting the bacteria's ability to manufacture essential proteins. The resulting physiological effect is the arrest of bacterial proliferation, restricting the functional viability of the bacterial population.


Enhanced Tissue Delivery and Anti-Inflammatory Effects

Azoxin exhibits a secondary mechanistic profile characterized by rapid accumulation within host immune cells (phagocytes), resulting in high concentrations within these cells. This mechanism supports a distinct action: the modulation of host inflammatory pathways, evidenced by reducing the release of pro-inflammatory cytokines such as IL-6 and IL-8. This modulation influences the physiological manifestation of local inflammation.


Limitations via Bacterial Resistance Mechanisms

The effectiveness of this mechanism is physiologically constrained when bacteria activate resistance. This occurs primarily through genetic modification of the 23S rRNA target site (e.g., methylation), which prevents drug binding, or via efflux pumps that actively expel the drug from the cell.

Dosage and Administration Information

Official Administration Guidelines for Azoxin (Azithromycin)

These instructions outline the established methods for taking Azoxin, based on standard prescribing information and product characteristics.


Administration Scope

Entity Official Label-Based Instruction
Route of Administration Oral (tablets, conventional suspension, extended-release suspension) and Intravenous (IV) by infusion.
Dosing Schedule (Adult) Common oral regimens include 500 mg once daily for 3 days, or 500 mg on Day 1 followed by 250 mg once daily on Days 2–5. Single doses of 1 g or 2 g are also used.
Timing in Relation to Meals Oral Tablets/Conventional Suspension: Can be taken with or without food. Extended-Release Suspension: Must be taken on an empty stomach (e.g., at least 1 hour before or 2 hours after a meal).
Preparation Requirements IV Solution: Requires reconstitution of the lyophilized powder and further dilution for slow infusion. Oral Suspension: Must be shaken well before each use and measured with a precise device.
Age-Group Rules Pediatric Dosing: Primarily weight-based (mg/kg), with safety not established for infants under 6 months for most uses. Older Adults: Standard adult dosing generally applies.
Missed Dose Rule If a dose is missed by 12 hours or less, take it immediately and resume the regular schedule. If more than 12 hours have passed, skip the missed dose and resume the next scheduled dose.
Special Procedural Conditions IV Administration: Must be given by slow infusion over 1 to 3 hours and must not be given as a bolus or intramuscular injection.

Instruction Classifications

Classification Pattern
Administration Method Type Oral / Intravenous
Frequency Pattern Once Daily / Single Dose / Once Weekly
Regulatory Basis Standard Prescribing Information
Use-Context Constraints Slow infusion required; Food dependency for certain formulations; Weight-based adjustment for children.

Connection to the Overall Use Protocol

These instructions define the required use by establishing the delivery route (oral versus IV), dictating the total quantity of the medicine over a specified duration (e.g., 5-day course), and setting the mandatory conditions (e.g., IV infusion rate, empty stomach requirement for specific forms). Following this structured protocol ensures administration aligns strictly with established therapeutic standards.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azoxin

This overview summarizes the research that has been conducted on Azoxin (Azithromycin) and what these studies suggest about its use. The information reflects findings from randomized controlled trials (RCTs), systematic reviews, and regulatory analyses. This section describes the evidence base but does not provide clinical advice or personal recommendations.


Evidence for Use in Acute Respiratory and Ear Infections

Research has explored Azoxin's role in addressing conditions characterized by acute or disruptive episodes, such as community-acquired pneumonia, middle ear infections (acute otitis media), and pharyngitis. The evidence for these short-term, acute uses is primarily derived from short-term randomized controlled trials (RCTs) and systematic reviews. These studies monitored short-term symptom changes, examining outcomes related to physical discomfort. Researchers sought to determine the rate at which changes in clinical signs were observed and the rate of microbiological eradication (bacterial clearance).

Studies report patterns observed in the studies related to reaching predefined recovery criteria during the observation period. Research describes resolution of outcomes related to physical discomfort like ear pain or fever. Reports also show that findings varied across studies examining this context. What remains uncertain is the full impact of use on antimicrobial resistance patterns in bacteria.


Long-Term Evidence and Follow-up for Chronic Lung Conditions

Azoxin was evaluated in specific chronic lung diseases, including Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, and Cystic Fibrosis. These were long-term RCTs where patients was observed in studies over many months. The studies explored the use of Azoxin as a maintenance measure in conditions characterized by cycles of stability and flare-ups. The main outcomes examined were outcomes describing episodic or acute changes, specifically the rate of episodes that met the criteria for an acute exacerbation. The emergence of macrolide-resistant organisms was noted in patient microbiological samples over the course of the long-term trials, and the long-term effects are not fully established beyond the one-year mark.

Key Studies & References

  1. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease (referencing exacerbation data)

Frequently Asked Questions (FAQ)

Common questions about Azoxin (FAQ)

Q: Can Azoxin affect my mood or sleep?

Official regulatory documents indicate that Azoxin may potentially affect a person's mood or sleep patterns. Reported side effects include insomnia (difficulty sleeping), somnolence (drowsiness), anxiety, agitation, and depression. This information is documented in the product's official safety labeling.

Q: Is it normal to feel a bit tired when first starting Azoxin?

Regulatory documents list fatigue and somnolence (drowsiness or feeling sleepy) as potential side effects reported in connection with the use of Azoxin. Such effects are part of the officially monitored safety profile for the medicine.

Q: Is Azoxin safe to use while driving?

The official product information notes that Azoxin may cause side effects such as dizziness and, less commonly, convulsions. Regulatory documents indicate that patients should be aware of these potential effects when considering driving or operating machinery.

Q: Does Azoxin show up on a standard drug test?

Azoxin (Azithromycin) is not typically included in common, routine drug screens, such as standard 5-panel tests. However, specialized laboratory tests designed to measure therapeutic drug levels of Azithromycin in the body are available.

Q: Will Azoxin change the effect of my birth control pills?

Official regulatory documentation does not provide consistent confirmation of a direct interaction between Azoxin and oral contraceptive pills. However, some clinical references indicate that concurrent use may increase the risk of pregnancy or cause breakthrough bleeding. This possibility is a factor noted in clinical considerations.

Q: How is the safety of Azoxin monitored after it's been approved?

The safety of Azoxin continues to be monitored after approval through a process called postmarketing surveillance. This involves regulatory agencies continuously collecting and analyzing reports of new or serious adverse reactions that were not identified during the initial clinical trials.

Q: Do official documents mention any mental health side effects for Azoxin?

Yes, official regulatory documents list psychiatric side effects based on post-marketing experience. These reported effects include aggression/aggressive reaction, anxiety, nervousness, agitation, and delirium.

Q: Does Azoxin make you more sensitive to the sun?

Yes, official regulatory labeling includes warnings for a condition called photosensitivity, which is an increased skin sensitivity to light. This is listed as a potential, though rare, adverse reaction associated with Azoxin use.

Q: Is Azoxin a generic medicine or a brand-name drug?

The active substance in Azoxin, Azithromycin, is widely available. According to official drug information from government health authorities, the substance is approved and marketed both under several brand names and as an accessible generic product.

Q: What is the chance of experiencing a serious side effect with Azoxin?

Regulatory labeling and clinical trial data indicate that most adverse reactions experienced with Azoxin are mild to moderate in severity. Official reports state that only a very small percentage of patients discontinued treatment in clinical trials due to side effects.

Q: Can Azoxin cause changes in blood pressure?

Official warnings focus on the serious cardiovascular risks associated with Azoxin, particularly the potential for QT interval prolongation and the serious irregular heart rhythm Torsades de Pointes. Post-marketing reports also include mentions of hypotension (low blood pressure) as a possible adverse reaction.

Q: When is the best time of day to take Azoxin?

The time of day for taking Azoxin is not strictly dictated by regulatory information, which focuses on the required dosing regimen. The overall treatment is typically structured around a regimen that dictates the dose be taken once daily.

Q: Can Azoxin affect my vision?

Official product reports confirm that transient visual impairment and blurred vision have been listed as possible adverse reactions. This information is included in the medicine's regulatory safety profile.

Q: Is Azoxin a medicine I have to take long-term?

Azoxin is primarily prescribed for short courses, most commonly a single dose or a 3-day or 5-day regimen. However, long-term use is documented for specific maintenance therapies in certain chronic conditions, which are subject to increased monitoring.

Q: Are there any common foods or drinks that interact with Azoxin?

Official drug interaction warnings state that concurrent use with aluminum- and magnesium-containing antacids should be avoided. These antacids can significantly reduce the absorption of Azoxin into the body.

Q: Can older people typically use Azoxin?

Older adults generally receive the standard adult dose. However, official information stresses that caution is required because geriatric patients may be more susceptible to torsades de pointes, a serious heart rhythm disorder.

Q: What happens if Azoxin interacts with another medicine?

A drug interaction means that the effects of either Azoxin or the other medicine can be changed. Examples include an interaction increasing the level of Azoxin in the blood or increasing the risk of serious side effects, such as the heart rhythm disorder caused by QT-prolonging drugs.

Q: Can children or teenagers use Azoxin?

Yes, regulatory documents describe Azoxin as suitable for most children and adolescents over 6 months of age for the approved uses. Dosing for this population is typically determined using a weight-based regimen.

Q: Are there specific symptoms that mean I should stop taking Azoxin?

Official warnings indicate that the medicine should be discontinued immediately and attention should be sought if signs of severe adverse reactions, such as hepatitis (liver injury) or severe allergic reactions (e.g., swelling of the face or a severe skin rash), occur.

Q: Why do some people feel no effect from Azoxin?

The effectiveness of Azoxin can be limited when the bacteria develop resistance mechanisms. These mechanisms, described in the official microbiology sections, include genetic changes that prevent the drug from binding to its target or the action of pumps that actively expel the drug from the bacterial cell.

Q: Are there specific monitoring tests recommended while taking Azoxin?

Monitoring is typically required when specific risks are present. For example, official documents recommend closely watching prothrombin time for patients taking Warfarin, and observing all patients for signs of hepatitis or potential cardiac events.

Q: Why might a doctor switch me from one similar drug to Azoxin?

Azoxin (Azithromycin) is chemically categorized as an azalide, which is distinct from older macrolides. Official pharmacological studies indicate that its unique structure allows it to achieve higher, sustained concentrations in body tissues, which may be a selection factor for medical professionals choosing a course of treatment.

Q: What is the reasoning behind the required monitoring when starting Azoxin?

The requirement for monitoring is directly driven by the need to mitigate the risks of specific serious adverse events. Official warnings detail the potential for QT interval prolongation (cardiotoxicity) and severe hepatotoxicity (liver injury), making observation necessary.

How should Azoxin be stored and disposed of?

How to Store and Dispose of Azoxin

Official regulatory guidelines strictly define the mandatory conditions for storing and disposing of Azoxin products to maintain stability and prevent environmental contamination.

Storage Requirements

Condition Requirement
Temperature Store in a cool, dry area, typically not exceeding 40 C (104 F).
Protection Keep in the original, tightly closed container and protect from direct sunlight and moisture.
Security The product must be stored in a secure area and kept out of the reach of children.
Stability The product is generally stable for at least 2 years under optimal storage conditions.

Disposal Instructions

Disposal must adhere to environmental regulations. Do not dispose of the product or its rinse water in household trash, sinks, drains, or other water bodies. Empty containers must be triple-rinsed and disposed of or recycled through an approved hazardous waste facility or official collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azoxin found in:

A-Z Index: